Celldex Therapeutics (CLDX) Receivables - Accured (2013 - 2026)

Celldex Therapeutics' Receivables - Accured history runs 14 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Receivables - Accured fell 21.67% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (down 21.67% YoY), while the FY2025 annual figure was $4.4 million, down 27.87% from the prior year.
• Receivables - Accured was $4.7 million for Q1 2026 at Celldex Therapeutics, up from $4.4 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $6.2 million in Q2 2025 to a low of $600000.0 in Q1 2023.
• Historically, Receivables - Accured has averaged $3.3 million across 5 years, with a median of $4.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Receivables - Accured slumped 38.46% in 2022, then soared 683.33% in 2024.
• A 5-year view of Receivables - Accured shows it stood at $800000.0 in 2022, then surged by 137.5% to $1.9 million in 2023, then jumped by 221.05% to $6.1 million in 2024, then dropped by 27.87% to $4.4 million in 2025, then increased by 6.82% to $4.7 million in 2026.
• The last three Receivables - Accured figures came in at $4.7 million (Q1 2026), $4.4 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.